The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.

The Institute of Cancer Research, London, has been recognised with a highly prestigious Queen’s Anniversary Prize for its world-leading research in cancer drug discovery.

Women with advanced ovarian cancer who begin treatment with olaparib are more likely to respond to the drug if it has been more than a year since their last round of chemotherapy, according to new research.